Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
The Ivy Brain Tumor Center is conducting a Phase 0 clinical trial to evaluate the combination of two targeted therapy drugs, abemaciclib and LY3214996, in patients with recurrent glioblastoma. The study aims to confirm that these drugs can effectively cross the blood-brain barrier and block cancer cell growth.
The Ivy Brain Tumor Center is collaborating with SonALAsense to develop and test sonodynamic therapy, a promising new treatment for recurrent glioblastoma. The Phase 0/2 clinical trial will assess the safety and efficacy of this non-invasive therapy in patients with glioblastoma.
A Phase 0 clinical trial shows ribociclib effectively targets glioblastoma cells and breaks the blood-brain barrier, offering a new treatment hope. The study identifies a potential mechanism of drug resistance, paving the way for a combined-drug regimen to overcome resistance.